Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257397 | 0.92 | OPRD1 (0.69) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL1743520 | 0.92 | OPRD1 (0.69) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL1894961 | 0.90 | OPRD1 (0.67) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL30340025 | 0.89 | OPRD1 (0.69) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL29389298 | 0.89 | OPRD1 (0.69) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL4705017 | 0.89 | OPRD1 (0.69) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL3178079 | 0.85 | OPRD1 (0.60) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrochloric Acid SCHEMBL3181605 | 0.84 | OPRD1 (0.59) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydromorphone SCHEMBL10031237 | 0.83 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydromorphone SCHEMBL2255 | 0.83 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996137-A2 | FLUIDIC TISSUE AUGMENTATION COMPOSITIONS AND METHODS | Kythera Biopharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | claimed |
| US-20080125414-A1 | Method of Treatment | PANOS THERAPEUTICS LIMITED (GB) | 2008-05-29 | — | — | US | claimed |
| EP-1492540-B1 | THE USE OF DEVAZEPIDE AS ANALGESIC AGENT | PANOS THERAPEUTICS LTD (GB) | 2007-10-17 | — | — | EP | claimed |
| WO-2007106457-A2 | FLUIDIC TISSUE AUGMENTATION COMPOSITIONS AND METHODS | KYTHERA BIOPHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| EP-1467718-B1 | METHOD OF TREATMENT OF A PATIENT REQUIRING ANALGESIA | ML LAB PLC (GB) | 2005-11-23 | — | — | EP | claimed |
| EP-1569654-A1 | USE OF DEVAZEPIDE IN COMBINATION WITH AN OPIOID ANALGESIC FOR POTENTIATING THE EFFECT OF THE ANALGESIC | ML Laboratories PLC (GB) | 2005-09-07 | — | — | EP | claimed |
| EP-1492540-A1 | THE USE OF DEVAZEPIDE AS ANALGESIC AGENT | ML Laboratories PLC (GB) | 2005-01-05 | — | — | EP | claimed |
| EP-1467718-A1 | METHOD OF TREATMENT OF A PATIENT REQUIRING ANALGESIA | ML Laboratories PLC (GB) | 2004-10-20 | — | — | EP | claimed |
| US-20040198723-A1 | Method of treatment | ML LABORATORIES PLC (GB) | 2004-10-07 | — | — | US | claimed |
| US-20040167146-A1 | Method of treatment | INNOVATA PLC (GB) | 2004-08-26 | — | — | US | claimed |
| US-20040142959-A1 | Method of treatment | INNOVATA PLC (GB) | 2004-07-22 | — | — | US | claimed |
| US-6713470-B2 | Method of treatment | ML LABORATORIES PLC (GB) | 2004-03-30 | — | — | US | claimed |
| US-20040043990-A1 | Method of treatment | JACKSON KAREN (GB) | 2004-03-04 | — | — | US | claimed |
| WO-2003103679-A1 | USE OF DEVAZEPIDE IN COMBINATION WITH AN OPIOID ANALGESIC FOR POTENTIATING THE EFFECT OF THE ANALGESIC | ML LABORATORIES PLC (GB) | 2003-12-18 | — | — | WO | claimed |
| WO-2003086409-A1 | THE USE OF DEVAZEPIDE AS ANALGESIC AGENT | ML LABORATORIES PLC (GB) | 2003-10-23 | — | — | WO | claimed |
| WO-2003080066-A1 | USE OF DEVAZEPIDE FOR THE TREATMENT OF CONSTIPATION | ML LABORATORIES PLC (GB) | 2003-10-02 | — | — | WO | claimed |
| US-20030153592-A1 | Method | INNOVATA PLC (GB) | 2003-08-14 | — | — | US | claimed |
| WO-2003061632-A1 | METHOD OF TREATMENT OF A PATIENT REQUIRING ANALGESIA | ML LABORATORIES PLC (GB) | 2003-07-31 | — | — | WO | claimed |
| US-20030139396-A1 | Constipation; administering devazepide | ML LABORATORIES PLC (GB) | 2003-07-24 | — | — | US | claimed |
| US-20240108638-A1 | METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT AND SKIN TIGHTENING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-04-04 | — | — | US | disclosed |
| EP-3692995-B1 | DEOXYCHOLATE FOR REDUCTION OF FAT | LUNDQUIST INST FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL CENTER (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-2968272-B1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3692995-A1 | DEOXYCHOLATE FOR REDUCTION OF FAT | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10653670-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| EP-2380576-B1 | Use of sodium deoxycholate for the non-surgical removal of fat | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20190290613-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-10258605-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| EP-1845938-B1 | METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT AND SKIN TIGHTENING | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20190015427-A1 | METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT AND SKIN TIGHTENING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-17 | — | — | US | disclosed |
| US-10058561-B2 | Methods and related compositions for reduction of fat and skin tightening | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180193309-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2018-07-12 | — | — | US | disclosed |
| US-20160279288-A1 | FLUIDIC TISSUE AUGMENTATION COMPOSITIONS AND METHODS | UNIV JOHNS HOPKINS (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160030389-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2968272-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | Alevere Medical Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105233287-A | Methods and related compositions for reduction of fat | LOS ANGELES BIOMED RES INST | 2016-01-13 | — | — | CN | disclosed |
| CN-101018553-B | Methods for reducing fat and related compositions | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR UCLA MEDICAL CENTER (US) | 2015-11-25 | — | — | CN | disclosed |
| US-20150051182-A1 | METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT AND SKIN TIGHTENING | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2015-02-19 | — | — | US | disclosed |
| US-8846066-B2 | Methods and related compositions for reduction of fat and skin tightening | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014143125-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140004206-A1 | METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT AND SKIN TIGHTENING | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2572718-A1 | Methods and related compositions for reduction of fat | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20100292650-A1 | Methods and Related Compositions for Reduction of Fat and Skin Tightening | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2010-11-18 | — | — | US | disclosed |
| US-7754230-B2 | Methods and related compositions for reduction of fat | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1996137-A2 | FLUIDIC TISSUE AUGMENTATION COMPOSITIONS AND METHODS | Kythera Biopharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080125414-A1 | Method of Treatment | PANOS THERAPEUTICS LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| EP-1845938-A1 | METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT AND SKIN TIGHTENING | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (US) | 2007-10-24 | — | — | EP | disclosed |
| EP-1492540-B1 | THE USE OF DEVAZEPIDE AS ANALGESIC AGENT | PANOS THERAPEUTICS LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007106457-A2 | FLUIDIC TISSUE AUGMENTATION COMPOSITIONS AND METHODS | KYTHERA BIOPHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070212385-A1 | Fluidic Tissue Augmentation Compositions and Methods | KYTHERA BIOPHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| CN-101018553-A | Methods for reducing fat and related compositions | LOS ANGELES BIOMED RES INST (US) | 2007-08-15 | — | — | CN | disclosed |
| EP-1748780-A1 | METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2006086038-A1 | METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT AND SKIN TIGHTENING | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060127468-A1 | Methods and related compositions for reduction of fat and skin tightening | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2006-06-15 | — | — | US | disclosed |
| US-20050267080-A1 | Methods and related compositions for reduction of fat | AESTHERX, INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005112942-A1 | METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2005-12-01 | — | — | WO | disclosed |
| EP-1467718-B1 | METHOD OF TREATMENT OF A PATIENT REQUIRING ANALGESIA | ML LAB PLC (GB) | 2005-11-23 | — | — | EP | disclosed |
| EP-1569654-A1 | USE OF DEVAZEPIDE IN COMBINATION WITH AN OPIOID ANALGESIC FOR POTENTIATING THE EFFECT OF THE ANALGESIC | ML Laboratories PLC (GB) | 2005-09-07 | — | — | EP | disclosed |
| EP-1467718-A1 | METHOD OF TREATMENT OF A PATIENT REQUIRING ANALGESIA | ML Laboratories PLC (GB) | 2004-10-20 | — | — | EP | disclosed |
| US-20040198723-A1 | Method of treatment | ML LABORATORIES PLC (GB) | 2004-10-07 | — | — | US | disclosed |
| US-20040167146-A1 | Method of treatment | INNOVATA PLC (GB) | 2004-08-26 | — | — | US | disclosed |
| US-20040142959-A1 | Method of treatment | INNOVATA PLC (GB) | 2004-07-22 | — | — | US | disclosed |
| US-6713470-B2 | Method of treatment | ML LABORATORIES PLC (GB) | 2004-03-30 | — | — | US | disclosed |
| US-20040043990-A1 | Method of treatment | JACKSON KAREN (GB) | 2004-03-04 | — | — | US | disclosed |
| WO-2003103679-A1 | USE OF DEVAZEPIDE IN COMBINATION WITH AN OPIOID ANALGESIC FOR POTENTIATING THE EFFECT OF THE ANALGESIC | ML LABORATORIES PLC (GB) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003080066-A1 | USE OF DEVAZEPIDE FOR THE TREATMENT OF CONSTIPATION | ML LABORATORIES PLC (GB) | 2003-10-02 | — | — | WO | disclosed |
| US-20030153592-A1 | Method | INNOVATA PLC (GB) | 2003-08-14 | — | — | US | disclosed |
| WO-2003061632-A1 | METHOD OF TREATMENT OF A PATIENT REQUIRING ANALGESIA | ML LABORATORIES PLC (GB) | 2003-07-31 | — | — | WO | disclosed |
| US-20030139396-A1 | Constipation; administering devazepide | ML LABORATORIES PLC (GB) | 2003-07-24 | — | — | US | disclosed |
| US-20020127275-A1 | Slow release pharmaceutical compositions and methods of preparation | BASF CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-20020110595-A1 | Slow release pharmaceutical compositions | BASF CORPORATION | 2002-08-15 | — | — | US | disclosed |
| WO-1998000143-A1 | SLOW RELEASE PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | KNOLL PHARMACEUTICAL COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1998000143-A1 | SLOW RELEASE PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | KNOLL PHARMACEUTICAL COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193309-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | OPRD1 3198/4885OPRM1 4633/4885OPRK1 2241/4885 |
| US-20190290613-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | OPRD1 3198/4885OPRM1 4633/4885OPRK1 2241/4885 |
| US-20160030389-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | OPRD1 3198/4885OPRM1 4633/4885OPRK1 2241/4885 |
| US-10653670-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | IDO1, FABP4, IDO2 | OPRD1 3198/4885OPRM1 4633/4885OPRK1 2241/4885 |
| US-10258605-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | IDO1, FABP4, IDO2 | OPRD1 3198/4885OPRM1 4633/4885OPRK1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.